Abstract
Promising novel biomarkers for the assessment of the acute kidney injury (AKI) or chronic kidney injury (CKI) include plasma levels of cystatin C, Neutrophil Gelatinase-associated Lipocalin (NGAL) and Interleukin-18 (IL-18) and urinary levels of NGAL, IL-18 and Kidney Injury Molecule-1 (KIM-1). These biochemical indices have been reported to be useful for evaluating the duration and severity of kidney disease and predicting progression and adverse clinical outcomes. Furthermore, these markers have given promising results in differentiating the various causes of AKI or CKI. Progressive renal failure is one of the main complications in HbS/β-thalassemia (HbS/β-thal). Early identification of patients at high risk of developing renal failure is of great importance as it may allow specific measures to delay the progression of renal damage and thus to reduce the incidence of end-stage renal failure and mortality. Continuing our previous studies (
impairment of GFR in 21/58 patients (36%);
increased plasma concentrations of NGAL and IL-18 in 34/58 (58%) and 58/58 (100%) patients, respectively;
increased and/or detectable urine concentrations of NGAL and IL-18 in 54/58 (93%) and 46/58 (79%) patients, respectively;
significant negative correlations between GFR and plasma NGAL and IL-18 (r=−0.735, p<0.0001 and r=−0.350, p<0.007, respectively) and
significant positive correlations between cystatin C and urine NGAL and IL-18 (binomial, p<0.005 and r=0.412, p<0.03, respectively).
These findings suggest that tubuloglomerular feedback is activated in almost all studied patients with HbS/b-thalassemia. Measurements of plasma and urine NGAL and IL-18 contribute significantly to the early detection and risk stratification of renal disease in these patients. However, prior to their clinical use, these biomarkers must undergo through rigorous validation in multiple cohorts.
Disclosures: No relevant conflicts of interest to declare.
Author notes
Corresponding author